Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for chagas' disease treatment

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6106-6109

  Serafim, Eliana Ometto Pavan ^a   De Albuquerque E Silva, Antonio Távora ^a   De Haro Moreno, Andréia ^a   De Oliveira Vizioli, Ednir ^a   Ferreira, Elizabeth Igne ^b   Peccinini, Rosângela Gonçalves ^a   Ribeiro, Maria Lucia ^a   Chung, Man Chin ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; HYDROXYMETHYLNITROFURAZONE; NITROFURAL; PRODRUG; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; BUFFER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHAGAS DISEASE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; HUMAN; HYDROLYSIS; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; COMPUTER SIMULATION; STATISTICAL MODEL; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; BUFFERS; COMPUTER SIMULATION; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; MALE; MODELS, STATISTICAL; NITROFURAZONE; PRODRUGS; RATS; RATS, WISTAR; TRYPANOCIDAL AGENTS;

EID: 84887462611     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02522-12     Document Type: Article

References (24)

1. Drugs for Neglected Diseases Initiative. 2013. Chagas disease. Global view. http://www.dndi.org/diseases-projects/diseases/chagas.html.
2. Moncayo A, Silveira AC. 2009. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz, 104(Suppl 1):17-30.
3. Coura JR, Viñas PA. 2010. Chagas disease: a new worldwide challenge. Nature 465:S6 -S7.
4. Cerecetto H, González M. 2011. Antiparasitic prodrug nifurtimox: revisiting its activation mechanism. Future Microbiol. 6:847-850.
5. Bot C, Hall BS, Bashir N, Taylor MC, Helsby NA, Wilkinson SR. 2010. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 54:4246-4252.
6. Bot C, Hall BS, Alvarez G, Di Maio R, González M, Cerecetto H, Wilkinson SR. 2013. Evaluating 5-nitrofurans as trypanocidal agents. Antimicrob. Agents Chemother. 57:1638-1647.
7. Zhou L, Stewart G, Rideau E, Westwood NJ, Smith TK. 2013. A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro. J. Med. Chem. 56:796-806.
8. Wilkinson SR, Bot C, Kelly JM, Hall BS. 2011. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr. Top. Med. Chem. 11:2072-2084.
9. Chung MC, Gonçalves MF, Colli W, Ferreira EI, Miranda MTM. 1997. Synthesis and in vitro evaluation of antichagasic dipeptide prodrugs of primaquine. J. Pharm. Sci. 86:1127-1131.
10. Chung MC, Güido RV, Martinelli TF, Gonçalves MF, Polli MC, Botelho KC, Varanda EA, Colli W, Miranda MT, Ferreira EI. 2003. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. Chem. 11: 4779-4783.
11. Davies C, Marino CR, Sánchez NO, Mora MC, Chung MC, Basombrío MA. 2010. Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease. Antimicrob. Agents Chemother. 54:3584-3589.
12. Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SS, Jacobson MP, Engel JC, McKerrow JH, Podust LM. 2010. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob. Agents Chemother. 54:2480-2488.
13. Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, Doyle PS. 2010. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob. Agents Chemother. 54:3326-3334.
14. Testa B, Mayer JM. 2003. Hydrolysis in drug and prodrug metabolism: chemistry, biochemistry, and enzymology, p 148 -162. VHCA/Wiley- VCH, Zurich, Switzerland.
15. Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. 2013. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin. Pharmacokinet. 52:399-414.
16. Trossini GH, Malvezzi A, Amaral AT, Rangel-Yagui CO, Izidoro MA, Cezari MH, Juliano L, Chin CM, Menezes CM, Ferreira EI. 2010. Trypanosoma cruzi. J. Enzym. Inhib. Med. Chem. 24:1-6.
17. Guido RVC, Ferreira EI, Nassute JC, Varanda EA, Chung MC. 2001. Decreased mutagenic activity of the prodrug NFOH-121 related to nitrofurazone. Rev. Cienc. Farm. 22:319-333.
18. Liu JP, Chow SC. 2002. Bridging studies in clinical development. J. Biopharm. Stat. 12:359-367.
19. Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P. 2012. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob. Agents Chemother. 56:2067-2073.
20. Friis GJ, Bundgaard H. 1996. Design and application of prodrugs, p 351-385. In Krogsgaard-Larsen P, Liljefords T, Madsen UA (ed), A textbook of drug design and development, 2nd ed. Harwood Academic Publishers, Newark, NJ.
21. Bundgaard H, Johansen M. 1980. Pro-drugs as drug delivery systems. VIII. Bioreversible derivatization of hydantoins by N-hydroxymethylation. Int. J. Pharm. 5:67-77.
22. Henderson GB, Ulrich P, Fairlamb AH, Rosenberg I, Pereira M, Sela M, Cerami A. 1988. Subversive substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc. Natl. Acad. Sci. U. S. A. 85:5374-5378.
23. Jockers-Scherübl MC, Schimer RH, Krauth-SiegeL RL. 1989. Trypanothione reductase from Trypanosoma cruzi: catalytic properties of the enzyme and inhibition studies with trypanocidal compounds. Eur. J. Biochem. 180:267-272.
24. Barbosa CF, Okuda ES, Chung MC, Ferreira EI, Cicarelli RM. 2007. Rapid test for the evaluation of the activity of the prodrug hydroxymethylnitrofurazone in the processing of Trypanosoma cruzi messenger RNAs. Braz. J. Med. Biol. Res. 40:33-39.